tetano
Editor, Senior Moderator
World Neurosurg. 2020 May 6. pii: S1878-8750(20)30932-3. doi: 10.1016/j.wneu.2020.04.222. [Epub ahead of print]
Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community.
Werner C[SUP]1[/SUP], Scullen T[SUP]2[/SUP], Mathkour M[SUP]2[/SUP], Zeoli T[SUP]1[/SUP], Beighley A[SUP]1[/SUP], Kilgore MD[SUP]1[/SUP], Carr C[SUP]1[/SUP], Zweifler RM[SUP]3[/SUP], Aysenne A[SUP]1[/SUP], Maulucci CM[SUP]2[/SUP], Dumont AS[SUP]2[/SUP], Bui CJ[SUP]2[/SUP], Keen JR[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
The coronavirus disease of 2019 (COVID-19) that is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been designated a pandemic by the World Health Organization, affecting 2.7 million individuals globally as of April 25, 2020 with over 187,000 deaths. A growing body of evidence supports central nervous system (CNS) involvement.
METHODS:
We conducted a review of the literature for articles concerning COVID-19 pathophysiology, neurological manifestations, and neuroscience provider recommendations and guidelines.
RESULTS:
CNS manifestations range from vague non-focal complaints to severe neurologic impairment associated with encephalitis. It is unclear whether neurological dysfunction is due to direct viral injury or systemic disease. The virus may affect brainstem pathways that lead to indirect respiratory dysfunction in addition to direct pulmonary injury. Necessary adaptations in patient management, triage, and diagnosis are evolving in light of ongoing scientific and clinical findings.
CONCLUSIONS:
This review consolidates the current body of literature regarding the neurological impact of coronaviruses, discusses the reported neurologic manifestations of COVID-19, and highlights recommendations for patient management. Specific recommendations pertaining to clinical practice for neurologists and neurosurgeons are provided.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
COVID-19; Encephalitis; Guideline; Neuroscience; SARS-COV-2
PMID:32387786DOI:10.1016/j.wneu.2020.04.222
Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community.
Werner C[SUP]1[/SUP], Scullen T[SUP]2[/SUP], Mathkour M[SUP]2[/SUP], Zeoli T[SUP]1[/SUP], Beighley A[SUP]1[/SUP], Kilgore MD[SUP]1[/SUP], Carr C[SUP]1[/SUP], Zweifler RM[SUP]3[/SUP], Aysenne A[SUP]1[/SUP], Maulucci CM[SUP]2[/SUP], Dumont AS[SUP]2[/SUP], Bui CJ[SUP]2[/SUP], Keen JR[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
The coronavirus disease of 2019 (COVID-19) that is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been designated a pandemic by the World Health Organization, affecting 2.7 million individuals globally as of April 25, 2020 with over 187,000 deaths. A growing body of evidence supports central nervous system (CNS) involvement.
METHODS:
We conducted a review of the literature for articles concerning COVID-19 pathophysiology, neurological manifestations, and neuroscience provider recommendations and guidelines.
RESULTS:
CNS manifestations range from vague non-focal complaints to severe neurologic impairment associated with encephalitis. It is unclear whether neurological dysfunction is due to direct viral injury or systemic disease. The virus may affect brainstem pathways that lead to indirect respiratory dysfunction in addition to direct pulmonary injury. Necessary adaptations in patient management, triage, and diagnosis are evolving in light of ongoing scientific and clinical findings.
CONCLUSIONS:
This review consolidates the current body of literature regarding the neurological impact of coronaviruses, discusses the reported neurologic manifestations of COVID-19, and highlights recommendations for patient management. Specific recommendations pertaining to clinical practice for neurologists and neurosurgeons are provided.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
COVID-19; Encephalitis; Guideline; Neuroscience; SARS-COV-2
PMID:32387786DOI:10.1016/j.wneu.2020.04.222